Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA (MRK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck KGaA May Withdraw Research from Portugal over Debt-Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 08:28am CET

German chemical company Merck KGaA (>> Merck KGaA) may withdraw future investments for research projects in Portugal worth tens of millions of euros unless the government hospitals stick to the agreed-upon debt repayments, German daily newspaper Financial Times Deutschland reports Monday.

Merck Portugal's manager Fritz Sacher told the paper the company's research projects are long-term and require mutual trust as a basis. "The Portuguese government's lacking payment habits undermine this trust," he is quoted as saying.

Portuguese government hospitals owe the pharmaceutical industry a total of more than 1.5 billion euros ($1.84 billion) and companies have to wait nearly 550 days on average until invoices are paid, FTD reports.

Some companies, including Roche Holding AG (ROG.VX), have already halted the sale of medications on credit to highly indebted countries like Portugal, Greece, Spain and Italy until outstanding debts are paid, the paper notes, but for many companies such drastic steps are difficult as they carry responsibility for people's wellbeing.

Withdrawing research projects is a way of putting pressure on the government, as Portugal is an attractive location for research investments, FTD says. "The conditions for certain research and human studies are as good as in the U.S., but it's significantly more cost-effective in Portugal," Sacher told the paper.

Newspaper website: http://www.ftd.de

Write to the Frankfurt Bureau at [email protected]

Stocks mentioned in the article : Merck KGaA
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
01/19 MERCK KGAA : Darmstadt, Germany Presents Data on Bifunctional Immunotherapy M782..
01/19 MERCK : Study Data from Merck KGaA Update Knowledge of Melanoma (Psychometric pr..
01/19 MERCK : Frost & Sullivan Applauds Merck KGaA Darmstadt, Germany for Successfully..
01/16 Health-conscious Nestle sells U.S. candy to Ferrero for $2.8 billion
01/16 MERCK : Darmstadt, Germany Presents Data on Bifunctional Immunotherapy M7824 at ..
01/10 Nestle frontrunner for Merck KGaA's consumer health business - Bloomberg
01/08 MERCK KGAA : Release according to Article 40, Section 1 of the WpHG [the German ..
2017 MERCK KGAA : - FDA Grants Breakthrough Therapy Designation for Avelumab in Combi..
2017 PFIZER : FDA Grants Breakthrough Therapy Designation for Avelumab in Combination..
2017 MERCK : Singapore’s IP Office to Grant MilliporeSigma’s Patent Appli..
More news
News from SeekingAlpha
01/10 Nestle frontrunner for Merck KGaA's consumer health unit
01/09 Merck (MKGAY) Presents At 36th Annual J.P. Morgan Healthcare Conference - Sli..
2017 WEEK IN REVIEW : 2017 Was Record Investment Year For China Life Science; Final W..
2017 Merck KGaA's Bavencio + Pfizer's Inlyta a Breakthrough Therapy for first-line..
2017 Britain's cost watchdog backs Novartis' MS med Extavia for use by NHS
Financials (€)
Sales 2017 15 340 M
EBIT 2017 3 417 M
Net income 2017 1 697 M
Debt 2017 9 777 M
Yield 2017 1,40%
P/E ratio 2017 20,15
P/E ratio 2018 20,61
EV / Sales 2017 1,41x
EV / Sales 2018 1,26x
Capitalization 11 777 M
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 108 €
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Michael Fletterich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA1.53%14 504
ABBVIE8.20%167 986
KYOWA HAKKO KIRIN CO LTD0.14%11 661
JAZZ PHARMACEUTICALS PLC13.20%9 175
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD21.33%7 233
CONVATEC GROUP-6.79%5 234